N. Polimeni

Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double‐blind, randomised, placebo‐controlled study

P. Portincasa, A. Tursi, S. Danese, 2013, Alimentary pharmacology & therapeutics.

Gut microbiota and non-alcoholic fatty liver disease: a narrative review.

L. Boccuto, L. Abenavoli, F. Luzza, 2021, Minerva gastroenterology.

Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.

A. Tursi, R. Faggiani, A. Lauria, 2017, Journal of gastrointestinal and liver diseases : JGLD.

Trends and characteristics associated with dietary triggers and psychological distress in patients with irritable bowel syndrome: a cross-sectional study.

L. Boccuto, L. Abenavoli, F. Luzza, 2021, European review for medical and pharmacological sciences.

The role of gluten-free diet in nonalcoholic fatty liver disease development.

L. Abenavoli, P. Doldo, F. Luzza, 2021, European review for medical and pharmacological sciences.

Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed.

D. Dumitrascu, L. Abenavoli, T. Larussa, 2021, Minerva gastroenterology.